Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$102.72 USD
-0.24 (-0.23%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $102.67 -0.05 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.72 USD
-0.24 (-0.23%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $102.67 -0.05 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
Top Analyst Reports for Walmart, IBM & Texas Instruments
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), IBM (IBM) and Texas Instruments (TXN).
Cyber Attack Fears Grip MedTech: 3 Safe Stocks
by Sweta Jaiswal
In the wake of rising incidences of cyber attacks in the MedTech space, we have zeroed down on some stocks which at present are safe-havens for investors.
Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake
by Zacks Equity Research
Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
Top Research Reports for Abbott, Gilead & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
Top Ranked Momentum Stocks to Buy for July 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 24th:
Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.
The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair
Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) poised to gain on continued strength in all geographies in Q2.
Top Stock Reports for Wells Fargo, IBM & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT).
Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
Housing Starts/Permits Disappoint; MS, USB and ABT Beat
by Mark Vickery
Morgan Stanley, U.S. Bank and Abbott all beat expectations, but new Housing Starts and Permits numbers were far below expectations.
Abbott (ABT) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Abbott (ABT) gains ground on new product launches and solid overall growth and delivers strong Q2 results.
These Companies are Earnings All-Stars
by Tracey Ryniec
It's not easy to beat on earnings nearly every quarter but these 5 companies are doing just that. Can they keep up their winning streaks?
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.
Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
by Zacks Equity Research
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
Top Stock Reports for Facebook, Amgen & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).
Tap Cardiovascular Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing cardiovascular devices market.